Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Traws Pharma (TRAW) EBT Margin (2016 - 2025)

Traws Pharma (TRAW) has disclosed EBT Margin for 13 consecutive years, with 9425.0% as the latest value for Q4 2024.

  • On a quarterly basis, EBT Margin fell 145714.0% to 9425.0% in Q4 2024 year-over-year; TTM through Sep 2025 was 4961.95%, a 5767434.0% increase, with the full-year FY2024 number at 62997.35%, down 5401593.0% from a year prior.
  • EBT Margin was 9425.0% for Q4 2024 at Traws Pharma, up from 14975.44% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 6719.64% in Q4 2021 to a low of 216400.0% in Q2 2024.
  • A 5-year average of 19671.0% and a median of 9366.07% in 2024 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: skyrocketed 495623bps in 2021, then tumbled -20831228bps in 2024.
  • Traws Pharma's EBT Margin stood at 10973.68% in 2020, then soared by 39bps to 6719.64% in 2021, then crashed by -52bps to 10239.29% in 2022, then grew by 22bps to 7967.86% in 2023, then fell by -18bps to 9425.0% in 2024.
  • Per Business Quant, the three most recent readings for TRAW's EBT Margin are 9425.0% (Q4 2024), 14975.44% (Q3 2024), and 216400.0% (Q2 2024).